NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Price Target & More

Get Started

$10.05 +0.28 (+2.87 %)

(As of 05/27/2018 04:00 PM ET)

Previous Close$10.05

Today's Range$9.78 - $10.18

52-Week Range$1.42 - $10.38

Volume1.44 million shs

Average Volume1.63 million shs

Market Capitalization$880.15 million

P/E Ratio-21.38

Dividend YieldN/A

Beta2.41

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ARWR

CUSIPN/A

Webwww.arrowheadpharma.com

Phone626-304-3400

Debt

Debt-to-Equity Ratio0.02

Current Ratio10.16

Quick Ratio10.16

Price-To-Earnings

Trailing P/E Ratio-21.38

Forward P/E Ratio-13.58

P/E GrowthN/A

Sales & Book Value

Annual Sales$31.41 million

Price / Sales28.02

Cash FlowN/A

Price / CashN/A

Book Value$1.30 per share

Price / Book7.73

Profitability

EPS (Most Recent Fiscal Year)($0.47)

Net Income$-34,380,000.00

Net Margins-199.55%

Return on Equity-50.05%

Return on Assets-40.83%

Miscellaneous

Employees93

Outstanding Shares87,580,000

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $0.65 million for the quarter, compared to analysts' expectations of $4.04 million. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

6 brokerages have issued 1 year price objectives for Arrowhead Pharmaceuticals' stock. Their predictions range from $4.00 to $13.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.

What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:

1. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
2. Cantor Fitzgerald analysts commented, "Arrowhead reiterated its recently disclosed timeline for returning to clinical development with at least two indications (AAT and HBV) in 1H18." (9/25/2017)

Who are some of Arrowhead Pharmaceuticals' key competitors?

Some companies that are related to Arrowhead Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma A/S (ASND), TESARO (TSRO), Portola Pharmaceuticals (PTLA), Horizon Pharma (HZNP), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Emergent Biosolutions (EBS), The Medicines (MDCO), Global Blood Therapeutics (GBT) and Heron Therapeutics (HRTX).

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:

Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
Dr. Bruce D. Given, Chief Operating Officer (Age 64)
Mr. Patrick O'Brien, Gen. Counsel (Age 54)
Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & Calando

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

Media headlines about ARWR stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.08 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (8.91%), RTW INVESTMENTS, LP (5.02%), BlackRock Inc. (3.92%), Acuta Capital Partners LLC (2.01%), Nexthera Capital LP (1.27%) and Millennium Management LLC (0.93%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, Alpine Global Management LLC and Barclays PLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, OppenheimerFunds Inc., Nexthera Capital LP, BlackRock Inc., Iguana Healthcare Management LLC, UBS Group AG, Tibra Equities Europe Ltd and GSA Capital Partners LLP. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $10.05.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $880.15 million and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]

MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		222 (Vote Outperform)
Underperform Votes:		158 (Vote Underperform)
Total Votes:		380

MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Arrowhead Pharmaceuticals in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible downside of 10.45%. The high price target for ARWR is $13.00 and the low price target for ARWR is $4.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Hold
Consensus Rating Score:	2.83	2.67	2.50	2.40
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$9.00	$6.30	$4.70	$2.70
Price Target Upside:	10.45% downside	9.22% downside	15.62% downside	27.03% downside

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History

Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/8/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$11.00	High
5/8/2018	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$13.00	High
3/27/2018	Jefferies Group	Initiated Coverage	Buy	$10.00	High
2/19/2018	Chardan Capital	Reiterated Rating	Buy	$7.00	Low
2/12/2018	B. Riley	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00	Medium
9/18/2017	William Blair	Upgrade	Market Perform ➝ Outperform		High

(Data available from 5/27/2016 forward)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates Chart

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.65)
2019 EPS Consensus Estimate: ($0.75)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.13)	($0.13)	($0.13)
Q2 2018	4	($0.20)	($0.13)	($0.17)
Q3 2018	5	($0.20)	($0.12)	($0.17)
Q4 2018	5	($0.20)	($0.13)	($0.18)
Q1 2019	3	($0.22)	($0.11)	($0.18)
Q2 2019	3	($0.23)	($0.11)	($0.19)
Q3 2019	3	($0.23)	($0.11)	($0.19)
Q4 2019	3	($0.24)	($0.10)	($0.19)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/1/2018		($0.19)					N/A
5/8/2018	Q2 2018	($0.19)	($0.18)	$4.04 million	$0.65 million	View	N/A
2/9/2018	Q1 2018	($0.14)	($0.18)	$8.71 million	$3.51 million	View	Listen
12/12/2017	Q4 2017	($0.12)	($0.14)	$7.32 million	$8.71 million	View	N/A
8/3/2017	Q3 2017	($0.13)	($0.07)	$5.29 million	$9.34 million	View	Listen
5/3/2017	Q2 2017	($0.1230)	($0.08)	$4.19 million	$8.99 million	View	Listen
2/6/2017	Q117	($0.20)	($0.17)	$13.24 million	$4.37 million	View	Listen
12/14/2016	Q4 2016	($0.33)	($0.31)	$0.04 million	$0.03 million	View	N/A
8/9/2016	Q316	($0.37)	($0.32)	$0.05 million	$39.58 million	View	N/A
5/10/2016	Q216	($0.37)	($0.35)	$0.26 million	$0.04 million	View	Listen
2/9/2016	Q1	($0.41)	($0.32)	$0.29 million	$0.04 million	View	N/A
12/14/2015	Q415	($0.39)	($0.42)	$0.14 million	$0.04 million	View	Listen
8/4/2015	Q315	($0.38)	($0.27)	$0.11 million	$0.12 million	View	N/A
5/11/2015	Q214	($0.35)	($0.33)	$110.00 million	$43.75 million	View	Listen
2/9/2015	Q114	($0.32)	($0.41)	$0.24 million	$0.17 million	View	N/A
11/25/2014	Q413	($0.25)	($0.33)	$0.04 million	$0.04 million	View	N/A
8/12/2014	Q313	($0.22)	($0.22)	$0.04 million	$0.04 million	View	N/A
5/6/2014	Q2 2014	($0.18)	($0.31)	$0.05 million	$0.04 million	View	N/A
2/4/2014	Q4	($0.18)	($0.33)	$0.05 million	$0.04 million	View	N/A
12/18/2013	Q4	($0.23)	($0.43)			View	Listen
8/7/2013	Q3 2013	($0.22)	($0.23)	$0.50 million	$0.04 million	View	N/A
5/9/2013	Q2 2013		($0.41)		$0.04 million	View	N/A
2/13/2013	Q1 2013		($0.33)			View	N/A
12/20/2012	Q4 2012		($0.43)			View	N/A
8/13/2012	Q3 2012		($0.71)			View	N/A
5/8/2012	Q2 2012		($0.44)			View	N/A
2/9/2012	Q1 2012		($0.25)			View	N/A
12/20/2011	Q4 2011		($0.39)			View	N/A
8/8/2011	Q3 2011	($0.20)	($0.26)			View	N/A
5/12/2011	Q2 2011	($0.20)	($0.18)			View	N/A
2/10/2011	Q1 2011		($0.20)			View	N/A
12/22/2010	Q4 2010	($0.30)	($0.28)			View	N/A
8/12/2010	Q3 2010	($0.50)	($0.06)			View	N/A
5/13/2010	Q2 2010	($0.40)	($0.33)			View	N/A
2/11/2010	Q1 2010		($0.30)			View	N/A
12/22/2009	Q4 2009		($0.60)			View	N/A
8/10/2009	Q3 2009		($0.60)			View	N/A
5/15/2009	Q2 2009		($1.20)			View	N/A
2/9/2009	Q1 2009		($1.90)			View	N/A
12/15/2008	Q4 2008		($2.14)			View	N/A
8/11/2008	Q3 2008		($1.90)			View	N/A
2/11/2008	Q1 2008		($1.40)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 44.58%

Insider Trading History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/24/2018	Douglas B. Given	Director	Sell	25,000	$6.63	$165,750.00
3/27/2018	Kenneth Allen Myszkowski	CFO	Sell	20,000	$8.00	$160,000.00	330,815
3/15/2018	Christopher Richard Anzalone	CEO	Sell	300,000	$7.43	$2,229,000.00	2,194,789
3/13/2018	Christopher Richard Anzalone	CEO	Sell	100,000	$7.43	$743,000.00	2,194,789
3/5/2018	Bruce D Given	COO	Sell	20,000	$6.73	$134,600.00	908,356
1/1/2018	Bruce D Given	COO	Sell	20,000	$3.69	$73,800.00	948,356
10/14/2016	Douglas B. Given	Director	Sell	12,000	$6.72	$80,640.00
8/23/2016	Kenneth Allen Myszkowski	CFO	Sell	6,900	$8.00	$55,200.00	128,789
8/22/2016	Kenneth Allen Myszkowski	CFO	Sell	13,100	$8.00	$104,800.00	128,789
12/30/2015	Kenneth Allen Myszkowski	CFO	Sell	23,347	$6.13	$143,117.11	135,000
10/28/2015	Mauro Ferrari	Director	Buy	400	$7.62	$3,048.00
10/9/2015	Mauro Ferrari	Director	Buy	1,900	$6.19	$11,761.00
1/5/2015	David L Lewis	Insider	Sell	15,000	$8.01	$120,150.00
10/15/2014	Christopher Richard Anzalone	CEO	Buy	16,000	$6.32	$101,120.00
10/1/2014	Charles Mckenney	Director	Sell	2,500	$14.70	$36,750.00
9/30/2014	David L Lewis	Insider	Sell	15,000	$15.02	$225,300.00
9/26/2014	Douglas B Given	Director	Sell	2,000	$15.24	$30,480.00
6/9/2014	Charles Mckenney	Director	Sell	22,000	$14.32	$315,040.00
2/12/2014	Kenneth Allen Myszkowski	CFO	Sell	16,000	$18.77	$300,320.00
2/7/2014	Edward W Frykman	Director	Sell	3,148	$15.98	$50,305.04

(Data available from 1/1/2013 forward)

Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines

Source:

Date	Headline
	Arrowhead Pharmaceuticals to Post FY2018 Earnings of ($0.76) Per Share, Cantor Fitzgerald Forecasts (ARWR) www.americanbankingnews.com - May 24 at 8:50 AM
	Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis www.bizjournals.com - May 21 at 8:46 AM
	Arrowhead Pharmaceuticals (ARWR) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - May 21 at 3:40 AM
	Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $610,000.00 www.americanbankingnews.com - May 19 at 1:55 AM
	Arrowhead Pharmaceuticals - Here Come The Institutions And What That Could Mean seekingalpha.com - May 18 at 5:17 PM
	Zacks: Analysts Expect Arrowhead Pharmaceuticals (ARWR) Will Post Earnings of -$0.19 Per Share www.americanbankingnews.com - May 17 at 11:15 PM
	Form SC 13G ARROWHEAD PHARMACEUTICAL Filed by: RTW INVESTMENTS, LP www.streetinsider.com - May 16 at 9:00 AM
	Investors Buy Large Volume of Arrowhead Pharmaceuticals Put Options (ARWR) www.americanbankingnews.com - May 16 at 6:56 AM
	Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT finance.yahoo.com - May 15 at 5:22 PM
	Wired News – Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases finance.yahoo.com - May 15 at 8:39 AM
	Arrowhead Pharmaceuticals Corp (ARWR) Reports Dosing of 1st Hepatitis B Patient in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV www.streetinsider.com - May 14 at 5:14 PM
	Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV finance.yahoo.com - May 14 at 9:55 AM
	Q3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Jefferies Group www.americanbankingnews.com - May 14 at 3:13 AM
	BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline www.reuters.com - May 13 at 8:57 AM
	Arrowhead Pharmaceuticals (ARWR) Upgraded to "Buy" at BidaskClub www.americanbankingnews.com - May 12 at 5:01 PM
	Jefferies Group Weighs in on Arrowhead Pharmaceuticals' FY2019 Earnings (ARWR) www.americanbankingnews.com - May 11 at 11:42 AM
	Q3 2018 EPS Estimates for Arrowhead Pharmaceuticals (ARWR) Boosted by William Blair www.americanbankingnews.com - May 11 at 10:01 AM
	Arrowhead Pharmaceuticals to Post Q3 2018 Earnings of ($0.18) Per Share, B. Riley Forecasts (ARWR) www.americanbankingnews.com - May 11 at 10:01 AM
	Q3 2018 Earnings Forecast for Arrowhead Pharmaceuticals (ARWR) Issued By Piper Jaffray www.americanbankingnews.com - May 11 at 10:01 AM
	5 Momentum Stocks Moving on Earnings www.nasdaq.com - May 10 at 5:15 PM
	Four momentum stocks to watch amid earnings reports finance.yahoo.com - May 10 at 5:15 PM
	Arrowhead Pharmaceuticals (ARWR) Releases Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - May 9 at 5:26 PM
	Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31 www.streetinsider.com - May 9 at 8:37 AM
	Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid ... globenewswire.com - May 9 at 8:37 AM
	BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18 www.reuters.com - May 9 at 8:37 AM
	Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Fiscal Q2 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 8:37 AM
	Arrowhead Pharmaceuticals (ARWR) Price Target Increased to $11.00 by Analysts at Piper Jaffray www.americanbankingnews.com - May 8 at 9:14 PM
	Arrowhead Pharmaceuticals (ARWR) Raised to "Overweight" at Cantor Fitzgerald www.americanbankingnews.com - May 8 at 9:14 PM
	Arrowhead Pharmaceuticals beats by $0.01, misses on revenue seekingalpha.com - May 8 at 5:20 PM
	Arrowhead Research: Fiscal 2Q Earnings Snapshot finance.yahoo.com - May 8 at 5:20 PM
	Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results finance.yahoo.com - May 8 at 5:20 PM
	Arrowhead Pharmaceuticals Ready To Break Out Of Its $7 Trading Range seekingalpha.com - May 5 at 5:20 PM
	Arrowhead Pharmaceuticals (ARWR) Rating Increased to Strong-Buy at ValuEngine www.americanbankingnews.com - May 2 at 11:35 PM
	$4.04 Million in Sales Expected for Arrowhead Pharmaceuticals (ARWR) This Quarter www.americanbankingnews.com - May 2 at 3:56 AM
	Brokerages Expect Arrowhead Pharmaceuticals (ARWR) to Post -$0.18 EPS www.americanbankingnews.com - April 30 at 11:20 AM
	Insider Selling: Arrowhead Pharmaceuticals (ARWR) Director Sells 25,000 Shares of Stock www.americanbankingnews.com - April 25 at 10:16 PM
	Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results finance.yahoo.com - April 24 at 5:10 PM
	Arrowhead Pharmaceuticals (ARWR) Set to Announce Quarterly Earnings on Tuesday www.americanbankingnews.com - April 24 at 5:17 AM
	Arrowhead Pharmaceuticals (ARWR) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 19 at 11:10 AM
	Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $4.04 Million www.americanbankingnews.com - April 15 at 4:05 AM
	Arrowhead Pharmaceuticals: Sneaky Upside Present Over The Course Of 2018 seekingalpha.com - April 13 at 5:19 PM
	Arrowhead Pharmaceuticals (ARWR) Expected to Post Earnings of -$0.18 Per Share www.americanbankingnews.com - April 13 at 11:34 AM
	Pre-Open Movers 04/11: (VHC) (LKM) (ARWR) Higher; (BW) (ALOG) (LAYN) Lower (more...) www.streetinsider.com - April 12 at 9:07 AM
	Arrowhead Pharmaceuticals (ARWR) Downgraded to "Buy" at BidaskClub www.americanbankingnews.com - April 10 at 11:29 AM
	Arrowhead Pharmaceuticals (ARWR) Lifted to Sell at ValuEngine www.americanbankingnews.com - April 8 at 1:29 PM
	Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™ finance.yahoo.com - April 5 at 9:37 AM
	Arrowhead Pharmaceuticals (ARWR) Upgraded to Buy at ValuEngine www.americanbankingnews.com - April 3 at 7:35 PM
	Arrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver Congress www.streetinsider.com - April 3 at 5:21 PM
	Top Stocks Under $10 www.forbes.com - April 3 at 8:23 AM
	Arrowhead Pharmaceuticals Inc (ARWR) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 1 at 5:48 AM

Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement

Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff